This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Align Technology (ALGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Align Technology (ALGN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 7.58% and 0.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
by Zacks Equity Research
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
What to Expect From These 3 MedTech Stocks This Earnings Season?
by Zacks Equity Research
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Align Technology (ALGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALGN Gears Up for Q1 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's first-quarter 2025 results are likely to reflect the strength in its Clear Aligner business.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Align Technology (ALGN) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ICUI Stock Declines Despite Plans for Offsetting Tariff Impacts
by Zacks Equity Research
ICU Medical unveils a strategic plan to offset new U.S. tariffs, aiming to protect margins and stability amid medtech market volatility and global trade shifts.